ONCOLOGY

Since 2003, PROMETRIKA has provided full or functional clinical services for more than a hundred phase 1 through 4 oncology trials in a wide variety of indications for large and small pharmaceutical and biotechnology companies as well as non-profit oncology research organizations.

Oncology represents one of PROMETRIKA’s top three therapeutic areas of experience. We are located in the heart of the innovation hub dedicated to the advancement of drug development for the treatment of cancer, and we are proud to contribute to that shared goal. Our broad range of oncology clinical trial experience include:

Expertise in
30 +
Cancers
  • + 20 Solid Tumor Indications
    • Breast Cancer
    • Carcinoid Pancreatic Neuroendocrine Tumors
    • Colorectal Cancer
    • Fallopian Tube Carcinoma
    • Lung Cancer
    • Melanoma
    • Neuroblastoma
    • Non-small Cell Lung Cancer
    • Ovarian Cancer
    • Peripheral Nerve Sheath Tumors
    • Pheochromocytoma Paraganglioma (PPG)
    • Primary Peritoneal Cancer (PPC)
    • Prostate Cancer
    • Renal Cell Carcinoma
    • Sarcoma/Soft Tissue Sarcoma
    • Solid Tumors
    • Squamous Cell Carcinoma
    • Ewing's Sarcoma
    • Bladder Cancer
    • Gastrointestinal Stromal Tumor (GIST)
  • + 12 Hematologic Malignancies
    • Acute Lymphoblastic Leukemia (ALL)
    • Acute Myelodysplastic Leukemia (MDS)
    • Acute Myelogenous Leukemia (AML)
    • Acute Myeloid Leukemia (AML)
    • Chronic Lymphocytic Leukemia
    • Cutaneous T-cell Lymphoma (CTCL)
    • Follicular Lymphoma
    • Multiple Myeloma
    • Peripheral T Cell Lymphoma
    • Hodgkin’s Lymphoma
    • B-Cell Non-Hodgkin's Lymphoma
    • Large B-cell Lymphoma (LBCL)

In addition to data analysis and reporting in these indications, PROMETRIKA has developed NDAs, including ISS and ISE, for AML and PPG.

  • 100+
    Oncology trials
  • Phase
    1-4
    Trials
  • Number of NDAs
    4

FDA Interaction

Our Sponsors have chosen PROMETRIKA’s biostatistics experts to present critical data before regulatory agency reviewers in CDER and CBER, and the Oncology Drugs Advisory Committee (ODAC). Our biostatistics and medical writing teams have prepared comprehensive responses to agency questions.

Oncology image montage

Client-focused Clinical Development Solutions

Our expertise in a wide range of cancer types helps us to offer specialized support for our clients. Our clinical development solutions include protocol development consultation by medical experts and biostatisticians who understand the nuances of collecting and evaluating data related to a particular cancer type. Our local and global regional monitoring teams are comprised of by oncology-focused CRAs.

We leverage the deep oncology expertise of our data science team members to build data capture systems and identify data anomalies that are specific to a cancer type. PROMETRIKA’s project teams are built from in-house subject matter experts with specific oncology therapeutic area experience, whose continual immersion and learning results in a high level of efficiency.